Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Eisai Enters Agreement With Minophagen; Gains Asian Access to Liver Disease Products

This article was originally published in PharmAsia News

Executive Summary

Under the shadow of Eisai's recent, massive "Dramatic Leap Plan" acquisitions, the company acquires the Asian development and marketing rights for Minophagen Pharmaceutical's Stronger Neo-Minophagen C and Glycyron products

You may also be interested in...

Asia Hep B Trials Could Preview U.S. Studies - Analyst

As clinical development programs mature in Asia, U.S. investors and analysts may increasingly look to Asian clinical trials to get a preview of a compound's potential success in U.S. markets

PharmAsia News Business Bulletin

A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts